Spain has begun funding its first dual immunotherapy for first-line treatment of metastatic colorectal cancer. The combination targets a rare tumour subtype and produced major gains over chemotherapy in a phase III trial.
On 1 September, Spain authorised the treatment for eligible adults with metastatic colorectal cancer whose tumours carry dMMR/MSI-H alterations. The combination of nivolumab and ipilimumab is the first dual immunotherapy financed for first-line treatment of this disease. Doctors measured it against conventional chemotherapy and nivolumab alone.
The decision also fits a wider European regulatory framework. Bristol Myers Squibb reports that the European Commission approved the combination for first-line treatment of adults with unresectable or metastatic MSI-H/dMMR colorectal cancer across the European Union, as well as Iceland, Liechtenstein and Norway.
The two-year result is stark. Seventy-four percent of patients who received the combination remained free of disease progression, compared with 11% of those given standard chemotherapy. The phase III CheckMate 8HW trial also found a 79% reduction in the risk of progression or death against chemotherapy and a 38% reduction against nivolumab monotherapy.
The European Commission approval covers all EU countries, plus Iceland, Liechtenstein and Norway, making the Spanish funding decision part of a broader European access pathway.
Nivolumab acts on PD-1. Ipilimumab blocks CTLA-4. These two immune-system brakes are targeted at the same time. According to Rocío García Carbonero, the combined effect is stronger because the two pathways are blocked together. The European approval provides the regulatory basis for first-line use. National health systems still decide when treatment is financed and how it reaches patients.
The Hospital público 12 de Octubre helped produce the trial evidence. Rocío García Carbonero coordinates the Digestive Tumours Unit within the hospital's Oncology Service. She was an investigator and co-author of the international trial, and included the first patient at the centre in 2020.
That patient access came early. People treated there received the strategy six years before it entered Spain's national public health system. The first patient treated in the trial achieved a complete response after two years of therapy and remained in sustained complete response several years after treatment ended.
For metastatic disease, that is a major change. Patients have traditionally relied on continuous conventional treatment. The new approach can produce deep responses and long periods without therapy.
The Spanish access decision also reflects a wider system challenge. Reporting that cites SEOM and the W.A.I.T. report puts the median interval between European authorisation and oncology-drug funding in Spain at 492 days; more than half of these medicines are introduced with restrictions on their approved indication.
The trial results appeared in The New England Journal of Medicine. In first-line treatment, the combination produced an objective response rate of 73%. Complete responses occurred in 35% of patients. A complete response means that no detectable lesions remained.
Materials prepared for ESMO 2026 also identify final overall-survival results from CheckMate 8HW. The analysis compares nivolumab plus ipilimumab with nivolumab or chemotherapy in patients with MSI-H/dMMR metastatic colorectal cancer. It adds a longer-term view to the progression-free survival findings.
The biology helps explain the result. dMMR/MSI-H tumours fail to repair errors made during DNA replication. They then accumulate thousands of mutations. That can make them resistant to traditional chemotherapy but especially sensitive to immunotherapy.
This subtype represents between 4% and 7% of metastatic colorectal cancer cases. It may also be linked to hereditary conditions such as Lynch syndrome. The group is small, but the treatment difference is clear.
Colorectal cancer affects the wider population too. It is the most frequently diagnosed cancer in Spain when both sexes are counted together and the second leading cause of cancer death worldwide. Some dMMR/MSI-H cases affect patients considerably younger than other colorectal cancers.
Practical information about how public healthcare brings new treatments to patients appears in earlier coverage of changes in access to medical care.
The funding decision adds a treatment for a clearly identified group to Spain's public system. Its results against chemotherapy and nivolumab show why dual immune blockade has changed the first-line standard for these patients.
The 12 de Octubre's role also matters. Research carried out inside Spain's public hospitals helped bring the treatment to patients in the trial. Coverage of fast-track cancer research in Spain has made the wider point: regulatory registration is only one stage. Later decisions on financing and the rules for inclusion in the public health system determine when patients can actually receive a new treatment.
